Loading...
Market
Which company will have better stock performance by end of 2024: AbbVie or Bristol Myers?
3
Resolution / Starting Odds
AbbVie outperforms Bristol Myers • 25%
Bristol Myers outperforms AbbVie • 25%
Both perform similarly • 25%
Both underperform market average • 25%
Stock price data from financial markets
Story
AbbVie Schizophrenia Drug Fails Mid-Stage Trials, Shares Plunge 12.8%
Nov 11, 2024, 03:05 PM
AbbVie Inc.'s experimental schizophrenia drug, Emraclidine, failed to meet the primary endpoints in two mid-stage Phase 2 clinical trials, leading to a significant drop in its stock price. The drug, acquired through AbbVie's $9 billion purchase of Cerevel Therapeutics, did not show statistically significant improvement in patients at week six of the trials. As a result, AbbVie's shares fell by as much as 12.8% in premarket trading and continued to decline throughout the day, ending down more than 11%. This outcome has benefited Bristol Myers Squibb, whose stock rose by 11.6% following the news. Bristol Myers recently received FDA approval for Cobenfy, the first new oral schizophrenia drug in decades, which launched in October.
View original story
Similar markets
Yes • 50%
No • 50%
Outperform • 25%
Underperform • 25%
Match performance • 25%
Significantly underperform • 25%
Nongfu Spring • 25%
Ganten • 25%
Both will perform equally • 25%
Other • 25%
Increases by more than 20% • 25%
Increases by 10% to 20% • 25%
Changes by less than 10% • 25%
Decreases • 25%
ABBV up, GMAB up • 25%
ABBV up, GMAB down • 25%
ABBV down, GMAB up • 25%
ABBV down, GMAB down • 25%
Roche (RHHBY) performs the best • 25%
Novo Nordisk performs the best • 25%
Eli Lilly performs the best • 25%
All perform similarly • 25%
Salesforce's stock price increases the most • 25%
Workday's stock price increases the most • 25%
Klarna's stock price increases the most • 25%
No significant change in stock prices • 25%
Nvidia • 25%
Apple • 25%
Microsoft • 25%
Google • 25%
FuboTV • 25%
Disney • 25%
Fox • 25%
Warner Bros. Discovery • 25%
Nvidia • 25%
Apple • 25%
Microsoft • 25%
Amazon • 25%
Outperforms all • 25%
Outperforms some • 25%
Matches performance • 25%
Underperforms all • 25%